LRRK2 and Parkinson disease: Most studies evaluating neuroprotection or effects on PD-related pathology have tested LRRK2 kinase inhibitors at high doses that reduce LRRK2 Ser935 > 90% and did not evaluate the dose-dependency of these outcomes16.